Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas

Jong Chul Park; T. Martin Ma; Lisa Rooper; Todd Hembrough; Robert D. Foss; Nicole C. Schmitt; Rishi Sawhney; Aaron Flanders; Hyunseok Kang

doi:10.1002/hed.25392

Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas

Jong Chul Park, T. Martin Ma, Lisa Rooper, Todd Hembrough, Robert D. Foss, Nicole C. Schmitt, Rishi Sawhney, Aaron Flanders, Hyunseok Kang

School of Medicine

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Background: Alterations in the human epidermal growth factor receptor-2 (HER2) pathway have been identified in a subset of salivary duct carcinomas. Dual HER2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in HER2-positive breast cancer, yet its efficacy in HER2-positive salivary duct carcinoma is unknown. Methods: We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics. Results: A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. Conclusion: Dual HER2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.

Original language	English (US)
Pages (from-to)	E100-E106
Journal	Head and Neck
Volume	40
Issue number	12
DOIs	https://doi.org/10.1002/hed.25392
State	Published - Dec 2018

Keywords

dual blockade
human epidermal growth factor receptor 2 (HER2)
human epidermal growth factor receptor 2 (HER2)
pertuzumab
salivary duct carcinoma
trastuzumab

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.25392

Cite this

@article{6de47fdcf9a84347bc88c9c72593d28e,

title = "Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas",

abstract = "Background: Alterations in the human epidermal growth factor receptor-2 (HER2) pathway have been identified in a subset of salivary duct carcinomas. Dual HER2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in HER2-positive breast cancer, yet its efficacy in HER2-positive salivary duct carcinoma is unknown. Methods: We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics. Results: A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. Conclusion: Dual HER2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.",

keywords = "dual blockade, human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 2 (HER2), pertuzumab, salivary duct carcinoma, trastuzumab",

author = "Park, {Jong Chul} and Ma, {T. Martin} and Lisa Rooper and Todd Hembrough and Foss, {Robert D.} and Schmitt, {Nicole C.} and Rishi Sawhney and Aaron Flanders and Hyunseok Kang",

note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2018",

month = dec,

doi = "10.1002/hed.25392",

language = "English (US)",

volume = "40",

pages = "E100--E106",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas

AU - Park, Jong Chul

AU - Ma, T. Martin

AU - Rooper, Lisa

AU - Hembrough, Todd

AU - Foss, Robert D.

AU - Schmitt, Nicole C.

AU - Sawhney, Rishi

AU - Flanders, Aaron

AU - Kang, Hyunseok

PY - 2018/12

Y1 - 2018/12

N2 - Background: Alterations in the human epidermal growth factor receptor-2 (HER2) pathway have been identified in a subset of salivary duct carcinomas. Dual HER2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in HER2-positive breast cancer, yet its efficacy in HER2-positive salivary duct carcinoma is unknown. Methods: We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics. Results: A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. Conclusion: Dual HER2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.

AB - Background: Alterations in the human epidermal growth factor receptor-2 (HER2) pathway have been identified in a subset of salivary duct carcinomas. Dual HER2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in HER2-positive breast cancer, yet its efficacy in HER2-positive salivary duct carcinoma is unknown. Methods: We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics. Results: A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with HER2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab. Conclusion: Dual HER2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.

KW - dual blockade

KW - human epidermal growth factor receptor 2 (HER2)

KW - pertuzumab

KW - salivary duct carcinoma

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85057450086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057450086&partnerID=8YFLogxK

U2 - 10.1002/hed.25392

DO - 10.1002/hed.25392

M3 - Article

C2 - 30478962

AN - SCOPUS:85057450086

SN - 1043-3074

VL - 40

SP - E100-E106

JO - Head and Neck

JF - Head and Neck

IS - 12

ER -

Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this